Document:

Unassociated Document

    
      Exhibit
10.1

    

     

    Equity
Ownership Transfer Agreement

    

    This
Agreement is entered into by and between the following parties the 26th day of
October 2009:

    

    Party A:
Guangzhou Konzern Pharmaceuticals Co., Ltd. (hereinafter referred to as
“Party A”), a wholly foreign-owned enterprise registered and legally existing in
PRC under PRC law, having its address at Room 702, Guangri Mansion, No.9 Siyou
Nan Road, Wuyang Xincheng, Guangzhou, with its legal representative being Mr.
Senshan Yang, and with China Medicine Corporation (an enterprise duly
incorporated and established under the laws of the Nevada State of USA and
listed on OTCBB in USA) being the sole shareholder of it; and

     

    Party B:
SINOFORM LIMITED (hereinafter referred to as “Party B”), a company registered
and legally exiting under the laws of British Virgin Islands, having its address
at 3rd Floor, Omar Hodge Building Wickhams Cayl Po Box362 Road Town, Tortol a
British Virgin Islands and with its executive director being Mr. Xiaoguang
Lin.

    

    Whereas:

    

    
      
        	
                1.

              	
                Guangzhou
      LifeTech Pharmaceuticals Co., Ltd. (hereinafter referred to as “LifeTech
      Pharmaceuticals”)  is a wholly foreign-owned enterprise approved
      by Bureau of Foreign Trade and Economic Cooperation of Conghua
      Municipality and is legally exiting, whose business license indicates:
      Registration Number: Qi Du Yue Sui Zong Zi No.009499; Registered Capital:
      RMB34,000,000.00; Term of Operation to expire on 21 August
      2036;

              
	 	 

      

    

    
      
        	
                2.

              	
                Party
      B is the sole shareholder of LifeTech Pharmaceuticals, legally holding
      100% equity interests in LifeTech Pharmaceuticals;

              
	 	 

      

    

    
      
        	
                3.

              	
                Party
      A intends to purchase all the equity interests in LifeTech Pharmaceuticals
      held by Party B, and Party B intends to sell to Party A all the equity
      interests in LifeTech Pharmaceuticals held by it (hereinafter referred to
      as “This Transaction”). Upon completion of such equity acquisition,
      LifeTech Pharmaceuticals will be changed to a wholly-owned subsidiary of
      Party A in accordance with law; and

              
	 	 

      

    

    
      	
              4.

            	
              In
      the principles of equality, voluntariness, fairness and good faith and
      upon adequate consultations, the Parties have entered into this Agreement
      with the following terms and
conditions.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Article
1 Equity Transfer

     

    1.1       
Party B agrees to in accordance with the provisions of this Agreement sell to
Party A its 100% equity interests in LifeTech Pharmaceuticals; and Party A
agrees to purchase such equity interests.

     

    1.2       
The Parties agree that the price for this equity transfer is RMB57,000,000.00.
Such transaction price is determined by the Parties through consultations on the
basis of the appraisal result of the auditing and appraisal of LifeTech
Pharmaceuticals carried out by the intermediary retained by Party A with the
base date being 30 August 2009.

     

    Article
2 Terms of Payment

     

    2.1       
Party A shall pay Party B the equity transfer price in the form of
currency.

     

    2.2       
Party A shall within three (3) working days after the execution of this
Agreement pay Party B RMB3,750,000.00 of the equity transfer price; before 30
March 2010 and after obtaining the approval on This Transaction from the Bureau
of Foreign Trade and Economic Cooperation of Conghua Municipality,
RMB25,000,000.00 of the equity transfer price shall be paid to Party B; within
three (3) working days after the passing of the equity interests in LifeTech
Pharmaceuticals to Party A, RMB3,250,000.00 of the equity transfer price shall
be paid to Party B; the residue RMB25,000,000.00 of the equity transfer price
shall be paid to Party B before 30 June 2010.

     

    Article
3 Passing of Equity Interests

     

    3.1       
Within three (3) working days after the execution by the Parties of this Equity
Transfer Agreement, Party B shall cause LifeTech Pharmaceuticals to apply to the
Bureau of Foreign Trade and Economic Cooperation of Conghua Municipality for
approval on change of shareholder and amendment of articles of association and,
after obtaining the approval from the Bureau of Foreign Trade and Economic
Cooperation of Conghua Municipality, to attend the change of shareholder
registration formalities with the AIC authority.

     

    3.2       
For the purpose of attending the formalities under 3.1, Party A and Party B
undertake to execute and issue to LifeTech Pharmaceuticals all necessary
documents in a timely manner.

     

    3.3       
The closing of equity transfer shall complete upon the passing of the equity
interests in LifeTech Pharmaceuticals to Party A.

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Article
4 Taxations

     

    4.1       
Party A and Party B will use their best efforts to jointly reduce transaction
costs and shall bear their respective costs incurred by the documentation work
and the retaining of professionals for the purpose of execution of this
Agreement and transacting the business hereunder.

     

    4.2       
Party A and Party B agree to bear the taxations payable by them respectively
under applicable law. Where no applicable law is in place in respect of the
obligor to bear certain taxation(s), such taxation(s) shall be borne by the
Parties equally.

     

    Article
5 Special Covenants on Debts of LifeTech Pharmaceuticals

     

    5.1       
The Parties confirm: on 30 August 2009 (the base date), the receivables and
payables between LifeTech Pharmaceuticals and the affiliate(s) of Party B have
been checked over, and the amount of the receivables equals the amount of the
payables from LifeTech Pharmaceuticals to the affiliate(s) of Party
B.

     

    5.2       
The Parties confirm: on 30 August 2009 (the base date), the receivables and
payables occurred in the course of the production and operation of LifeTech
Pharmaceuticals (except those between LifeTech Pharmaceuticals and the
affiliate(s) of Party B) have been checked
over, and the total amount of such receivables and the inventories equals the
total amount of payables from LifeTech Pharmaceuticals to others.

     

    5.3       
The Parties confirm: on 30 August 2009 (the base date), the balance of the bank
loans of LifeTech Pharmaceuticals was RMB89,800,000.00. Such bank loans shall be
repaid by Party A.

     

    5.4       
The Parties confirm: as to the bank loans under 5.3, Party A shall within three
(3) days after the execution of this Agreement pay RMB20,000,000.00 to Guangzhou
Rural Credit Union on behalf of LifeTech Pharmaceuticals and shall within three
(3) days after the execution of this Agreement pay RMB30,000,000.00 to Guangzhou
Rural Credit Union on behalf of LifeTech Pharmaceuticals; with respect to the
residue of such bank loans, Party B is to coordinate the lender bank to perform
the current loan agreement(s).

     

    Article
6 Special Covenant on the Land Use Right in the Assets to Be
Transferred

     

    Party B
has made disclosure and Party A has had knowledge of: as to all the land use
right currently used by LifeTech Pharmaceuticals at No.16 Guangcong Road,
Conghua Economic and Technological Development Zone, read from the books,
LifeTech Pharmaceuticals still owes land grant premium to Conghua District
Government (or Land Administration Authority); however, on the basis of the
privity reached and followed by LifeTech Pharmaceuticals and Conghua District
Government for many years, such land premium can actually be paid through
deduction by the part of taxations paid to Conghua District Government, which
can be retained by it and returned to LifeTech Pharmaceuticals.  The
Parties hereto agree: such land premium shall continue to be paid by LifeTech
Pharmaceuticals through deduction by the part of the taxations paid to Conghua
District Government; where any change occurs to the policy and the government
demands payment of the land premium for such land lot and other amounts in
relation thereto, Party B shall be liable to make the payment.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Article
7 Placement of Employees of LifeTech Pharmaceuticals

     

    Party A
agrees that, after the acquisition, LifeTech Pharmaceuticals shall continue to
perform the labor Agreements with the current employees.  Party A
undertakes: the LifeTech Pharmaceuticals taken over by it will not illegally
dismiss any employee with an annual salary lower than RMB100,000, nor will it
cut the remuneration or other treatments of the employees; after the completion
of the closing, any performance, rescission, extension, dispute or compensation
issues in relation to the labor Agreements with the employees will be handled by
LifeTech Pharmaceuticals in accordance with the PRC Labor Agreement
Law.

     

    Article
8 Handing-over

     

    8.1       
The Parties agree: on the second day after Party A’s repayment of the
RMB20,000,000.00 of bank loan of LifeTech Pharmaceuticals in accordance with 5.4
and the payment of the first installment of equity transfer price in an amount
of RMB3,750,000.00 in accordance with 2.2 (“Handing-over Date”), the
handing-over of the assets of LifeTech Pharmaceuticals shall start.

     

    8.2       
On the day prior to the Handing-over Date, the Parties shall deliver to each
other the Power of Attorneys duly signed by the legal representatives in favor
of the authorized representatives so as to facilitate the particular
handing-over issues.

     

    8.3       
Handing-over Methods

     

    8.3.1    
As to inventories (including finished products <with a residue life time of
more than half a year>, raw materials, trademarks, semi-finished products and
other movable properties in connection with the business and production of
LifeTech Pharmaceuticals) (Party B is to provide a temporal inventory statement
as of 30 August 2009 for reference and the factual inventories shall be as
indicated by the actual counting on the Handing-over date), receivables,
payables, machinery and office equipments, if no discrepancy is discovered in
the course of the counting by the authorized representatives of the Parties, the
handing-over shall be deemed as having been completed upon signing on the
handing-over list by the representatives of the Parties jointly.

     

    8.3.2    
Handing-over of Land and House Title Certificates of LifeTech
Pharmaceuticals

     

    Since the
land and house title certificates of LifeTech Pharmaceuticals have been
deposited with Conghua Real Estate Administration Bureau for the purpose of
obtaining bank loans by it, the Parties agree: the handing-over shall be deemed
as having been completed upon Party B obtaining the photocopies of such land and
house title certificates from Conghua Real Estate Administration Bureau and
providing the same to Party A.

     

    8.3.3    
Handing-over of Intellectual Properties of LifeTech Pharmaceuticals

     

    As to the
intellectual properties currently owned by LifeTech Pharmaceuticals, Party B is
to provide Party A with the photocopies of the relevant title certificates or
approval documents of the same, for which a receipt shall be signed by the
authorized representative of Party A; within two (2) working days after Party
A’s payment of the third installment of the transfer price (RMB3,250,000.00) in
accordance with 2.2 and Party A’s repayment of the RMB50,000,000.00 of the bank
loans of LifeTech Pharmaceuticals in accordance with 5.4, Party B shall provide
Party A with the originals of the relevant title certificates or approval
documents of such intellectual properties.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Party B
shall disclose to Party A the relevant product outsourcing Agreement(s) and
shall give a brief introduction to the performance status of such Agreements in
the mean time.

     

    8.3.4    
Handing-over of Other Assets

     

    The
handing-over of other assets (if any) shall be deemed as having been completed
upon signing on the handing-over list by the representatives of Party A and
Party B.

     

    8.4      
Any debts and liabilities incurred by the operation and management of LifeTech
Pharmaceuticals before the Handing-over Date and not disclosed by Party B shall
be borne by Party B; where LifeTech Pharmaceuticals has made any payment in
respect of such debts or liabilities, Party B shall indemnify in full LifeTech
Pharmaceuticals the payment(s) made by it.  Any and all costs,
expenses, legal liabilities, operation and management liabilities in relation to
the operation of LifeTech Pharmaceuticals incurred after the Handing-over Date
shall be borne by Party A and the LifeTech Pharmaceuticals after the
Handing-over Date.

     

    Article
9 Transitional Period Arrangement

     

    9.1       
Party A and Party B agree: the time period from the Handing-over Date to the
closing date shall be the transitional period.

     

    9.2       
During the transitional period, Party A, Party B and the LifeTech
Pharmaceuticals taken over by Party A shall not dispose of the land, houses,
machinery equipments, office equipments and other intangible assets of LifeTech
Pharmaceuticals, shall not increase the bank debts of LifeTech Pharmaceuticals,
and shall not provide security for loans in favor of other enterprises in the
name or with the assets of LifeTech Pharmaceuticals.

     

    9.3       
The company chop of LifeTech Pharmaceuticals shall be kept under joint custody
of Party A and Party B. Within three (3) working days after Party B’s receipt of
the third installment of the equity transfer price (RMB3,250,000.00) paid by
Party A, the Parties shall attend the formalities of destroying such company
chop with the competent public security authority. After the old company chop is
destroyed, LifeTech Pharmaceuticals shall start to use a new company
chop.

     

    9.4       
The Parties agree: during the period from the Handing-over Date to the
completion of the closing of this equity transfer, the profits and losses of
LifeTech Pharmaceuticals shall be enjoyed and borne by Party A and no adjustment
is to be made by the Parties to the transfer price.

     

    Article
10 Special Covenant on Transfer of Equity Interests in Guangzhou LifeTech
Medicine Technologies Co., Ltd.

     

    MCWALTS
INVESTMENT HOLDINGS LTD., an affiliate of Party B, is holding 100% of the equity
interests in Guangzhou LifeTech Medicine Technologies Co., Ltd.; and Party A
intends to purchase such equity interests. Party B agrees to cause MCWALTS
INVESTMENT HOLDINGS LTD. to sell to Party A the 100% equity interests held by it
in Guangzhou LifeTech Medicine Technologies Co., Ltd., with the terms and
conditions to be agreed upon by Party A and MCWALTS INVESTMENT HOLDINGS LTD. in
a separate equity transfer agreement.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Article
11        Party A’s Representations and
Warranties

     

    11.1       
Party A is an enterprise legal person legally established and existing, which
has obtained all necessary authorizations and approvals to enter into this
Agreement.

     

    11.2       
The conclusion and performance of this Agreement are not in breach of any
Agreement binding on it or any other legal instrument; otherwise, all the
relevant legal liabilities shall be borne by Party A.

     

    11.3       
Party A is of adequate capacity to perform its obligations under this
Agreement.

     

    11.4       
Party A undertakes: to actively cooperate with Party B in attending the relevant
handing-over issues and to, as per the reasonable requirements of Party B,
provide in a timely manner the true and complete documents in relation to this
equity transfer.

     

    11.5       
Party A undertakes to actively cooperate with Party B in attending the
examination and approval formalities (if necessary) with the competent foreign
exchange administration authority in relation to Party B’s repatriation overseas
of the proceeds from the equity transfer, and to, as per the reasonable
requirements of Party B, provide in a timely manner the true and complete
documents in relation to this equity transfer.

     

    11.6       
Except where the business license of LifeTech Pharmaceuticals is revoked in
accordance with law, Party A will not rescind or terminate this Agreement for
any reason.

     

    Article
12        Party B’s Representations and
Warranties

     

    12.1       
Party B is an enterprise legal person legally established and existing, which
has obtained all necessary authorizations and approvals to enter into this
Agreement.

     

    12.2       
The conclusion and performance of this Agreement are not in breach of any
Agreement binding on it or any other legal instrument; otherwise, all the
relevant legal liabilities shall be borne by Party B.

     

    12.3       
Party B legally owns 100% of the equity interests in LifeTech Pharmaceuticals;
furthermore, there exists no pledge, mortgage or any other right alleged by a
third party in relation to such equity interests, nor any other circumstance
restricting the transfer thereof.

     

    12.4       
Party B undertakes: there exists no long-term equity investment made by LifeTech
Pharmaceuticals in other enterprises, nor any commitment to make any long-term
equity investment in other enterprises.

     

    12.5       
Party B undertakes: the materials, Agreements and documents in all the respects
of the assets, debts, business, financial status, certificates and licenses of
LifeTech Pharmaceuticals provided by Party B to Party A for the purpose of this
transaction are true, accurate, complete, fully reflecting the assets, rights,
obligations, business, liabilities and other relevant information of LifeTech
Pharmaceuticals, and without material (to incur losses to LifeTech
Pharmaceuticals in an amount over RMB1,000,000.00) concealing, omission,
exaggeration or misleading; as to any such material concealing, omission,
exaggeration or misleading in disclosure, Party B shall bear compensation
liabilities.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    12.6       
Party B undertakes: LifeTech Pharmaceuticals has all necessary qualifications,
authorizations and approvals to carry out its current business.

     

    12.7       
Party B undertakes: as of the date of execution of this Agreement, LifeTech
Pharmaceuticals is not involved in any undisclosed material (to incur losses to
LifeTech Pharmaceuticals in an amount over RMB1,000,000.00) litigation,
arbitration or administrative penalty or any material economic
dispute.

     

    12.8       
During the period from the date of execution of this Agreement to the
Handing-over Date, Party B undertakes: to maintain the ordinary production and
operation of LifeTech Pharmaceuticals, to assure the capital of LifeTech
Pharmaceuticals not to be unreasonably transferred, to assure the assets of
LifeTech Pharmaceuticals not to be disposed of without consent from the Parties,
and to assure the bank debts of LifeTech Pharmaceuticals not to increase;
otherwise, Party B shall compensate the LifeTech Pharmaceuticals taken over by
Party A or Party A the losses incurred thereby.

     

    12.9       
Except where the business license of LifeTech Pharmaceuticals is revoked in
accordance with law, Party B will not rescind or terminate this Agreement for
any reason.

     

    Article
13        Confidentiality
Obligation

     

    The
Parties hereto agree: the content of this Agreement and any document, materials
and information obtained from the other Party under any provision of this
Agreement (“Confidential Information”) shall be kept in confidentiality by the
Parties and shall not be disclosed to a third party without consent from the
providing Party, except the disclosure by either Party as per the requirement of
applicable law, government authority or stock exchange.  The Parties
shall procure the professionals retained by them to comply with this provision
and shall bear the liabilities in relation to the obligations of such
professionals to comply with this provision.

     

    Article
14        Breach of Agreement
Liabilities

     

    14.1       
Party A undertakes: where any false statement, material omission or material
misunderstanding exists in the representations, undertakings or warranties made
by Party A, Party A fails to perform its obligations under this Agreement
properly and adequately, or Party A breaches its confidentiality obligations,
Party A shall compensate LifeTech Pharmaceuticals and Party B all the direct and
indirect losses incurred thereby (including litigation, legal proceedings,
arbitration, claims, evaluation and expenses).

     

    14.2       
Party B undertakes: where any false statement, material omission or material
misunderstanding exists in the representations, undertakings or warranties made
by Party B, Party B fails to perform its obligations under this Agreement
properly and adequately, or Party B breaches its confidentiality obligations,
Party B shall compensate Party A all the direct and indirect losses incurred
thereby (including litigation, legal proceedings, arbitration, claims,
evaluation and expenses).

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    14.3       
Where either of the Parties unilaterally terminates this Agreement without a
legitimate reason, such Party shall pay the other Party breach of Agreement
damages in an amount of RMB20,000,000.

     

    14.4       
Where Party A fails to perform its obligations under 5.4 to repay the bank loans
of LifeTech Pharmaceuticals, breach of Agreement damages shall be paid to Party
B by Party A at a rate of 0.05% of the amount due and payable for each day in
default, which is to be computed till Party A ‘s repayment in full of such bank
loans.

     

    14.5       
Any amendment to or rescission of this Agreement shall not affect the right of
the non-defaulting Party to pursue the breach of Agreement liabilities of the
defaulting Party under this Agreement.

     

    14.6       
Any Party’s failure or delay to exercise any of its rights to pursue the breach
of Agreement liabilities of the defaulting Party shall not constitute a waiver
of such right; any Party’s partial exercise of its rights to pursue the breach
of Agreement liabilities of the defaulting Party shall not affect its exercise
of other rights.

     

    Article
15    Force Majeure

     

    15.1       
Force Majeure means earthquake, war, riot, natural disasters like plague and
other exempting events agreed by the Parties hereto.

     

    15.2       
Where this Agreement is rendered unable to be performed or unable to be fully
performed, the Party suffering such force majeure event shall notify the other
Party such force majeure event and shall within five (5) working days after the
end of the force majeure event provide a description of the event together with
an effective certificate showing the reasons that this Agreement is unable to be
performed or unable to be fully performed or that the performance of this
Agreement needs to be postponed.  Party A and Party B shall on the
basis of the extent of affection on the performance of this Agreement
decide through consultations whether to terminate this Agreement, to partially
exempt the performance of this Agreement, or to postpone the performance of this
Agreement.

     

    15.3       
Under the premise that neither of the Parties is at fault, the inability to
perform all or part of the obligations under this Agreement shall not be deemed
as a breach, provided that all necessary measures shall be taken to reduce or
eliminate the losses caused by the force majeure event to the extent
possible.

     

    15.4       
Neither of the Parties shall bear responsibilities in relation to the losses
suffered by or expenses increased to the other Party due to the force majeure
event.

     

    Article
16        Effect, Amendment and Termination
of Agreement

     

    16.1       
Upon being signed by the legal representative(s) or authorized representative(s)
of the Parties and being approved by the Bureau of Foreign Trade and Economic
Cooperation of Conghua Municipality, this Agreement shall take effect and be
legally binding on the Parties, which shall terminate automatically upon being
duly performed.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    16.2       
Upon this Agreement taking effect, unless otherwise agreed by the Parties in
consensus, neither of the Parties may amend the same unilaterally; any amendment
to or modification of this Agreement shall take effect only after being
confirmed by the Parties in written form.

     

    Article
17        Applicable Law

     

    
      17.1       
The
conclusion, performance and interpretation of this Agreement shall be governed
by PRC law.

    

     

    17.2       
Where any provision of this Agreement is in conflict with any law or regulation
currently effective, such provision shall be void. The voidance of any provision
shall not affect the effect of other provisions or this Agreement as a
whole.  The Parties hereto shall agree on a new provision to supercede
such void provision.

     

    Article
18        Dispute Resolution

     

    The
Parties shall consciously and faithfully perform this Agreement.  In
the event of any dispute, it shall be resolved through consultations; where such
consultations fail, either of the Parties may refer the dispute to China
International Economic and Trade Arbitration Commission South China
Sub-Commission for arbitration held in accordance with the arbitration rules
currently effective.  The arbitration shall be held in
Shenzhen.  The arbitral award shall be final and binding on the
Parties.

     

    Article
19        Miscellaneous

     

    19.1       
The Schedules hereto are an integral part of this Agreement, which together with
the text hereof constitute the entirety of this Agreement.

     

    19.2       
In the event of any issue not provided for herein, the Parties shall settle the
same through amiable consultations.

     

    19.3       
This Agreement is made in both Chinese and English languages; in the event of
any discrepancy between the two versions, the Chinese version shall
prevail.

     

    19.4       
This Agreement is made in six (6) copies; either of the Parties shall hold one
(1) with the rest to be submitted to competent authorities for the purposes of
examination and approval or registration; each of the original copies shall be
of the same legal effect.

    

    (No text
is contained on the remainder of this page.)

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (This
signature page of the Equity Transfer Agreement contains no text.)

     

    Party
A:  Guangzhou Konzern Pharmaceutical Co., Ltd. (Chop)

     

    Legal or
Authorized Representative (Signature):

     

    
      
        	 	 	 	 	 
	
                      
                  /s/
      SanShan Yang

                

              	 	 	
              	 
	
                      
                  Mr.
      SanShan Yang

                

              	 	 	
              	 
	
                      
                  Chairman
      & CEO

                

              	 	 	
              	 

      

    

     

    Party
B:  SINOFORM LIMITED (Chop)

     

    Legal or
Authorized Representative (Signature):

     

    
      
        
          	 	 	 	 	 
	
                        
                          
                      /s/
      Daoming Mo

                    

                  

                	 	 	
                	 
	
                        
                          
                      Mr.
      Daoming Mo

                    

                  

                	 	 	
                	 
	
                        
                    Chairman
      & CEOSUBSCRIPTION
AGREEMENT

    CHINA
US EVENTS CORP.

    a Delaware
corporation. 

    
      

    

     

    The undersigned (sometimes referred to
herein as “Subscriber”) hereby subscribes to purchase the number of shares of
Common Stock (the “Shares”) of CHINA US EVENTS CORP., a Delaware Corporation
(the “Company”) indicated below in accordance with the terms and conditions of
the ProspectusProspectusand any future supplement thereto (the
“Prospectus”).  The undersigned understands that, if accepted, its
subscription is irrevocable, but that
it may be rejected in the sole discretion of the Company, for any
reason.

    

    In
consideration for the acceptance by the Company of this Subscription Agreement,
the

    Subscriber
hereby agrees, represents and warrants as follows:

    

    1.           Acceptance
or Rejection of Subscription.  The Company shall have the right to
accept or reject this subscription in whole or in part.  If rejected,
the Subscriber's check and Subscription Documents (as defined below) shall be
promptly returned to the Subscriber.  If accepted, the Subscriber's
check will be forwarded directly to the Company, and the Subscriber's Investor
Questionnaire and Subscription Agreement (collectively referred to herein as the
"Subscription Documents") will be retained by the Company.

    2.           Closing.  If the
Company has not received and accepted subscriptions and the closing date is not
extended in the sole discretion of the Company for up to an additional ninety
(90) days (the "Closing Date"), the Offering will terminate and any unaccepted
investments in the possession of the Company and Subscription Documents shall be
promptly returned to the Subscriber.

    3.           Agreement to
Indemnify.  The Subscriber hereby agrees to indemnify and hold
harmless the Company and all of its directors, officers, agents and employees
from any and all damages, losses, costs and expenses (including reasonable
attorneys' fees) which they may incur (I) by reason of the Subscriber's failure
to fulfill any of the terms and conditions of this Agreement, (ii) by reason of
the Subscriber's breach of any of the Subscriber's representations, warranties
or agreements contained herein or in the Investor Questionnaire, and (iii) with
respect to any and all claims made by or involving any person, other than the
Subscriber, claiming any interest, right, title, power or authority regarding
the Subscriber's purchase of Shares.  The Subscriber further agrees
and acknowledges that this indemnification agreement shall survive any sale or
transfer, or attempted sale or transfer, of any portion of the Subscriber's
Shares or upon the Subscriber's death.

    4.           Representations, Warranties and
Covenants.  The Subscriber hereby represents, warrants, and
covenants that:

    (i)           Subscriber
acknowledges that the Shares are covered by a Prospectus and Registration
Statement on Form S-1 and have been registered under the Securities Act with the
Securities and Exchange Commission.

    (ii)          Subscriber
(a) has received a copy of the Prospectus and has carefully reviewed and
understands the Prospectus and (b) understands that, except as set forth in the
Prospectus or unless made to investor in writing, no representations or
warranties have been made to the Subscriber by the Company or any of its
officers directors, employees, agents or affiliates, and (c) agrees that,
in connection with the purchase of the Shares, it is not relying upon any
information concerning the Company, other than (i) that contained in this
Prospectus and (ii) on the results of its own independent
investigation.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    (iii)         Subscriber
understands that (a) no governmental authority has passed upon the accuracy or
completeness of the Prospectus or has made any finding or determination
concerning the appropriateness or suitability of an investment in the Shares and
(b) no governmental authority has recommended or endorsed, or will recommend or
endorse, an investment in the Shares.

    (iv)         Subscriber
is acquiring the Shares for Subscriber’s own account and not for the account of
others and for investment purposes only and not with a view to or for the sale,
offer for sale, transfer, assignment, resale or distribution thereof, in whole
or in part.

    (v)       
  All subsequent offers and sales of the Shares by Subscriber shall be
made in compliance with the Securities Act, pursuant to registration under the
Securities Act or pursuant to an exemption from such registration.

    (vi)         Subscriber
understands that the Shares are being offered and sold to it in reliance on
specific exemptions from the registration requirements of U.S. federal and state
securities laws and that the Company is relying upon the truth and accuracy of
the representations, warranties, agreements acknowledgments and understandings
of Subscriber set forth in the Subscription Agreement and Investor Questionnaire
in order to determine the applicability of such exemptions and the suitability
of Subscriber to acquire the Shares.

    (vii)        Subscriber
has adequate net worth and means of providing for his current needs and personal
contingencies to sustain a complete loss of his investment in the Shares and has
no need for liquidity in this investment.

    (viii)       The
Company has made available to Subscriber, its counsel and advisors, if any, the
opportunity to ask questions of, and receive answers from the Company and its
representatives, concerning the terms and conditions of an investment in the
Shares, and has given it access to any requested information, documents,
financial statements, books and records relative to the Company and an
investment in the Shares.

    (ix)         
If the Subscriber is a corporation, it is duly organized, validly existing and
in good standing under the laws of the jurisdiction of its incorporation, and if
the Subscriber is a partnership or other organization, it is duly organized,
validly existing and in good standing under the laws of its jurisdiction of
organization.

    (x)           (a)
If the Subscriber is a corporation, the execution, delivery and performance of
this Agreement have been duly authorized by all necessary corporate action, (b)
if the Subscriber is a partnership or other organization, the other governing
documents to enter into this Agreement and to consummate the transactions
contemplated hereby and all necessary consents and approvals required by the
partnership agreement or other governing documents have been obtained, and (c)
for both corporations and partnerships, this Agreement constitutes a legal,
valid and binding obligation of the Subscriber, enforceable against the
Subscriber in accordance with its terms, except to the extent that
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium and similar laws affecting creditors' rights
generally.

    (xi)          Subscriber
is aware that investing in the Shares is speculative and involves a high degree
of risk and that any right to transfer its Shares in the Company is limited and
restricted by law, and this Subscription Agreement.

    (xii)         Subscriber
has evaluated the risks of investing in the Shares and has substantial
experience in making investment decisions of this type or is relying on his
advisors or Purchase Representative, if applicable, in making this investment
decision.

    (xiii)        Subscriber
understands that the shares subject to this Subscription Agreement have been
registered under a Registration Statement on Form S-1, filed with the Securities
and Exchange Commission, and until such Registration Statement has been declared
effective by the Securities and Exchange Commission, a legend may be placed on
any certificate representing the Shares substantially as follows:

    “The shares represented by this
certificate have not been registered under the Securities Act of
1933.  These shares have been acquired for investment and not for
distribution or resale.  They may not be mortgaged, pledged,
hypothecated, or otherwise transferred without an effective registration
statement for such shares under the Securities Act of 1933 or an opinion of
counsel for the corporation that registration is not required under such
Act.”

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    The foregoing representations,
warranties, and covenants and all other information which the Subscriber has
provided to the Company concerning the Subscriber and the Subscriber's financial
condition (or concerning the entity or organization which the subscriber
represents and its financial condition) are true and accurate as of the date
hereof.

    5.           Subscription Agreement Binding on
Heirs, Etc.  This Subscription Agreement shall be
binding upon the Subscriber's heirs, successors estate, legal representatives
and assigns, and shall be construed in accordance with the laws of the State of
New York.

    6.           Execution
Authorized.  If this Subscription Agreement and the other
relevant Subscription Documents are executed on behalf of a corporation,
partnership, trust or other entity, the Subscriber has been duly authorized and
empowered legally to represent such entity and to execute this Subscription
Agreement and such Subscription Documents and all other instruments in
connection with the purchase of the Shares, and the Subscriber's signature is
binding upon such entity.

    7.           Legal Representation/Conflict of
Interest.  The Subscriber, by executing this Subscription
Agreement acknowledges, represents and agrees that (a) the Company has retained
legal counsel to represent it in connection with the preparation of this
Subscription Agreement and the Prospectus; (b) such legal counsel has prepared
such documents with a view to the interests of the Company only and has not
undertaken to represent the interest of the Subscriber and that no
attorney-client relationship or fiduciary duty exists between such legal counsel
and the Subscriber, notwithstanding that the Subscriber's investment may pay,
directly or indirectly, for such legal services; (c) the Subscriber has been
advised to have such legal documents reviewed by the Subscriber's own
independent attorney and/or other advisors; and (d) the services performed by
such legal counsel have been limited to the preparation of such documentation at
the request and direction of the Company and such legal counsel has not
undertaken to conduct any investigation whatsoever concerning the facts, risks
or circumstances concerning or relating to the investment and/or the background
or financial qualifications of the Company.

    8.           Governing Law, and
Venue.  This Agreement shall be construed in accordance with,
and governed by, the laws of the State of New York with venue proper in New
York.

    9.           Definition of
Terms.  The terms used herein, if not otherwise defined herein,
shall have the meanings attributed to such terms in the
Prospectus.  All pronouns and any variations thereof used herein shall
be deemed to refer to the masculine, feminine, neuter, singular or plural as the
identity of the person or persons herein may require.

    10.           Number of
Shares.  The undersigned hereby subscribes for Units as
follows:

    ________ $0.04 per
share

    

    All
checks should be made payable to:  “CHINA US EVENTS
CORP.”

     

    11.           Taxpayer Identification Number
Certification.

     

    
      
        	
                ______________________________

              	 
      	
                ___________________________

              
	
                Social
      Security or Tax I.D. No.

              	
                  

              	
                Social
      Security or Tax I.D. No.

              

      

       

    

    I declare that the number shown in this
Subscription Agreement is my correct taxpayer identification number and/or
social security number (or I am waiting for a number to be issued to me), that I
have read and understood the foregoing documents, and that I desire to purchase
the shares herein under the terms set forth in this Subscription
Agreement.

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                Signature

                              	 
      	
                                 

                              	 
      	
                                Signature

                              	 	
                                 

                              
	
                                Date

                              	
                                  

                              	
                                 

                              	
                                  

                              	
                                Date

                              	 	
                                 

                              

                      

                    

                  

                

              

            

          

        

      

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    TYPE
OF OWNERSHIP (Check one)

    

    
      
        	
                9   INDIVIDUAL                      INDIVIDUAL
      OWNERSHIP

                 (One signature
      required)

              	 	
                9     COMMUNITY
      PROPERTY

                 (one
      signature required if interest held in one name, i.e., managing spouse;
      two signatures required if interest held in both names)

              
	
                9  JOINT
      TENANTS WITH RIGHT OF SURVIVORSHIP

                 (both or all parties
      must sign)

                 

              	 	
                9     CORPORATION

                 (Please
      include certified Corporate Resolution authorizing
    signature)

              
	
                9          PARTNERSHIP

                (Please
      include a copy of the Statement of Partnership Agreement authorizing
      signature)

              	 	
                9          TRUST

                 (Please include a
      copy of the Trust Agreement)

              

      

    

    

    _________________________________________________________

    [Please
print above the exact name(s) in which the Convertible is to be
held]

    

    IN WITNESS WHEREOF, the
undersigned has executed this Subscription Agreement this _____ day of
________________, 2006.

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            	
                                     

                                  	 
      	
                                     

                                  
	
                                    Subscriber
      #1 Signature

                                  	 
      	
                                    Subscriber
      #2 Signature

                                  
	 
      	 
      	 
      
	
                                     

                                  	 
      	
                                     

                                  
	
                                    Subscriber
      #1 Print or Type Name and

                                  	 
      	
                                    Subscriber
      #2 Print or Type Name and

                                  
	
                                    Title
      (if applicable)

                                  	 
      	
                                    Title
      (if applicable)

                                  
	 
      	 
      	 
      
	
                                     

                                  	 
      	
                                     

                                  
	
                                    Telephone
      Number

                                  	 
      	
                                    Telephone
      Number

                                  
	 
      	 
      	 
      
	
                                     

                                  	 
      	
                                     

                                  
	
                                    Street
      Address

                                  	 
      	
                                    Street
      Address

                                  
	 
      	 
      	 
      
	
                                     

                                  	 
      	
                                     

                                  
	
                                    City

                                  	
                                    State

                                  	
                                    Zip

                                  	
                                      

                                  	
                                    City

                                  	
                                    State

                                  	
                                    Zip

                                  

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    

    
      
        	
                SUBSCRIPTION
      ACCEPTED:

              
	
                CHINA
      US EVENTS CORP.

              
	 
      	 
      
	
                By:

              	
                  

              
	 
      	
                Authorized
      Officer

              
	
                Dated:

              	
                  

              

      

    

     

    
      
         

      

      
        4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]